Our goal: develop innovative molecular solutions to advance the diagnosis of infectious diseases and antibiotic resistances

Mobidiag is a commercial stage, fast-growing Finnish-French biotechnology company. At Mobidiag, we develop and market innovative diagnostic solutions for Gastrointestinal Infections, Antimicrobial Resistance Management, Healthcare Associated Infections (HAIs), Respiratory Infections and Sepsis.

Based on well-established qPCR and microarray technologies, Mobidiag offers a broad range of tests and instruments. These include a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases adapted to laboratories of all sizes. They allow detection of most clinically relevant bacteria, parasites, viruses and antibiotic resistances.

Established in 2000, Mobidiag has started serving the European clinical diagnostics market with the multiplex Prove-it™ product family.

In 2013, Mobidiag (Finland) merged with a diagnostic platform developer Genewave (France) and a stool-based clinical assay development company Amplidiag (Finland). As a result, complementing capabilities and offering were gathered to offer industry-leading diagnostic solutions.

Combining expertise in sales, marketing, business, molecular diagnostics, microbiology, software development, bioinformatics, biochemistry and engineering, Mobidiag is able to manufacture and commercialise its own proprietary solutions: Amplidiag® and Novodiag®.